title: CHA2DS2-VAS(C) and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation.
abstract: BACKGROUND
  CHA2DS2-VASc and CHADS2 scores were derived and validated for stroke-risk stratification in patients who have a diagnosis of atrial fibrillation (AF). We hypothesized that these scores would predict adverse cardiovascular events even in the absence of AF.
  
  
  METHODS
  The CHA2DS2-VASc and CHADS2 scores for 2010 patients with sick sinus syndrome who underwent pacemaker implantation and were enrolled in the Mode Selection Trial (MOST) were calculated. The association of these risk scores with main trial end points, including the composite of death and stroke, were evaluated to determine whether the associations differed by history of AF.
  
  
  RESULTS
  Of the 2010 patients, 12% had a CHA2DS2-VASc score of 0-1, 16% had a score of 2, 41% had a score of 3-4, and 31% had a score ≥ 5 (the distribution for CHADS2 was similar); 42% had a clinical history of AF. Both scores were associated with death or stroke (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.05-1.23 for each 1-point increase in CHA2DS2-VASc; P = 0.001; HR, 1.11; 95% CI, 1.02-1.21 for each 1-point increase in CHADS2; P = 0.016). Association of scores with outcomes of death, stroke, and heart failure hospitalization were not different for patients with vs those without a history of AF (interaction P ≥ 0.55 for CHA2DS2-VASc and ≥ 0.30 for CHADS2).
  
  
  CONCLUSIONS
  Both CHA2DS2-VASc and CHADS2 scores predict risk of death or stroke in patients with sick sinus syndrome, regardless of AF history. These scores could be risk-stratification tools for clinical events that might respond to new therapies—ie, anticoagulation or other interventions—even in the absence of AF.
authors.affiliation: Hackensack University Medical Center, Hackensack, New Jersey, USA. Electronic address: tayavg@aol.com.
authors.forename: Taya V
authors.initials: TV
authors.lastname: Glotzer
authors.affiliation: Duke Clinical Research Institute, Durham, North Carolina, USA.
authors.forename: Anne S
authors.initials: AS
authors.lastname: Hellkamp
authors.affiliation: Duke Clinical Research Institute, Durham, North Carolina, USA.
authors.forename: Kerry L
authors.initials: KL
authors.lastname: Lee
authors.affiliation: Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, Florida, USA.
authors.forename: Gervasio A
authors.initials: GA
authors.lastname: Lamas
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D010138:Pacemaker, Artificial / Q000009:adverse effects*; D011237:Predictive Value of Tests; D011379:Prognosis; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D012804:Sick Sinus Syndrome / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D015996:Survival Rate / Q000639:trends; D014481:United States / Q000453:epidemiology